Next 10 |
home / stock / hrmy / hrmy articles
Roy Bingham, CEO of BDSA, anticipates substantial growth in the U.S. cannabis market, projecting sales to reach nearly $46 billion by 2028. This gr...
Growth stocks are attractive to many investors, as above-average financial growth helps these stocks easily grab the market's attention and pro...
Tuesday, Harmony Biosciences (NASDAQ:HRMY) announced the acquisition of Epygenix Therapeutics, adding a rare epilepsy franchise to its ex...
Jeffrey Dierks, Chief Commercial Officer at Harmony Biosciences (NASDAQ:HRMY), reported a large exercise of company stock options on March 18, acco...
Gainers SciSparc Ltd. (NASDAQ: SPRC) shares climbed 80% to $6.14 after the company announced it received notice of acceptance from the Australian...
U.S. stocks traded lower, with the Dow Jones falling more than 50 points on Tuesday. Here are some major stocks recording gains in today’s se...
Continued Strong Growth with WAKIX® (pitolisant) Net Revenue of $160.3 Million for Third Quarter 2023; Increased ~37% Year-over-Year Average...
Harmony Biosciences Holdings, Inc. (NASDAQ: HRMY) shares are trading higher on Monday as the stock rebounds after falling Friday on Phase 3 INTUNE ...
U.S. stocks traded lower toward the end of trading, with the Nasdaq Composite falling more than 1% on Friday. The Dow traded down 0.02% to 33,...
News, Short Squeeze, Breakout and More Instantly...
Harmony Biosciences Holdings Inc. Company Name:
HRMY Stock Symbol:
NASDAQ Market:
Harmony Biosciences Holdings Inc. Website:
HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) HARMONY BIOSCIENCES ACKNOWLEDGES U.S. FOOD & DRUG ADMINISTRATION (FDA) ACTION DENYING THE CITIZEN PETITION FOR WAKIX® (PITOLSIANT) PR ...
HARMONY BIOSCIENCES RECEIVES U.S. FOOD AND DRUG ADMINISTRATION APPROVAL FOR WAKIX® (PITOLISANT) IN PEDIATRIC PATIENTS WITH NARCOLEPSY WAKIX is the first-and-only FDA-approved non-scheduled treatment option for excessive daytime sleepiness in pediatric patients 6 years of age and ol...
2024-06-21 16:15:08 ET Citigroup analyst issues UNDERPERFORM recommendation for HRMY on June 21, 2024 01:00PM ET. The previous analyst recommendation was Underperform. HRMY was trading at $29.96 at issue of the analyst recommendation. The overall analyst consensus : BUY....